MEDI3726

MEDI3726

About MEDI3726

MEDI3726 (ADCT-401) is partnered with MedImmune/AstraZeneca. MEDI3726 is a prostate-specific membrane antigen (PSMA)-targeted antibody drug conjugate (ADC). It is composed of PSMA-specific IgG1 monoclonal antibody J591 engineered to enable site-specific conjugation to a highly cytotoxic DNA cross-linking pyrrolobenzodiazepine (PBD) dimer via a cleavable dipeptide linker.

MEDI3726 is being evaluated in a Phase I clinical trial in patients with metastatic castration resistant prostate cancer (ClinicalTrials.gov identifier NCT02991911).

PSMA Illustration